Morning Trend | EDGE MEDICAL leads the surge with increased volume, and the pharmaceutical sector shows widening divergence

EDGE MEDICAL-B (2675.HK) saw a significant increase in trading volume yesterday, forming a golden cross on the daily chart, with the MACD opening above the zero line, confirming a short-term bullish pattern. The K-line recorded a strong bullish candle, breaking through the resistance of the 5-day and 10-day moving averages, with significant inflow of main funds, indicating a strong willingness to participate. The pharmaceutical sector is showing high differentiation overall, with structural market conditions and sector rotation intensifying, as market funds tentatively position themselves in emerging innovative drug targets. From a technical perspective, the moving average system shows a bullish arrangement, with strong support built on the short-term technical front; intraday trading volume is active, and there are clear signs of funds clustering. If the volume continues to cooperate, there is a chance to challenge previous highs in the future. However, the divergence within the sector is increasing, and the risk of fund outflow from some high-priced stocks cannot be ignored. In terms of the industry environment, the medical innovative drug sector is supported by policies, driven by research and development progress and performance improvement, attracting long-term funds for increased allocation. Short-term fluctuations are mainly due to the switching of hot topics and the accelerated rhythm of sector rotation, necessitating caution against high-level funds realizing floating profits. Operational advice: Right-side traders should pay attention to the support situation when the price pulls back to the 5-day moving average during the day and participate appropriately in swing opportunities. Monitor the cooperation of main funds and intraday anomalies, and be cautious of the risk of reversal in internal sector sentiment leading to profit-taking. From a medium to long-term perspective, one should carefully assess the matching degree of valuation and fundamentals, and implement dynamic risk management. Industry risks include policy fluctuations, research and development progress falling short of expectations, and high valuation correction pressure. It is crucial to avoid blindly chasing highs in operations, and it is recommended to combine phased position building with stop-loss and take-profit strategies for stable participation